Novo Nordisk A/S vs Open Text Corporation — how do they compare? Novo Nordisk A/S trades at $46.19 (market cap $207.85B), while Open Text Corporation trades at $23.71 (market cap $5.80B). The key difference: Novo Nordisk A/S is far larger — about 35.8× Open Text Corporation's market cap, and Open Text Corporation pays the higher dividend (4.67%). Which is the better fit depends on your goals.
| NVO | OTEX | |
|---|---|---|
Market Cap | $207.85B | $5.80B |
Sector | Health | Technology |
52-Week High | $63.98 | $39.69 |
52-Week Low | $35.29 | $20.01 |
Enterprise Value | $222.55B | $10.81B |
Dividend Yield | 3.81% | 4.67% |
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $46.28, down 3.05% today, with technical indicators showing neutral signals. The company maintains strong fundamentals with Q2 2026 EPS beating expectations at $0.96 versus $0.77 estimate, continuing a pattern of earnings outperformance. Revenue growth remains solid with 2025 revenue reaching $309.1B and net income margin of 33.14%. Analyst sentiment remains positive with 57.9% recommending Buy, though recent news highlights competitive pressures from Eli Lilly in the GLP-1 market.
NVO presents a compelling investment case with robust profitability metrics including 59.82% ROE and attractive valuation at 11.62 P/E. However, increasing competition in weight-loss drugs and pricing pressures create headwinds. The stock's current technical neutrality suggests potential consolidation near current levels, with fundamental strength supporting long-term growth prospects despite near-term competitive challenges.
Open Text Corporation (OTEX) trades at $23.62, down 4.45% in the past 24 hours, with a bullish technical signal despite bearish moving averages. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $1.23 exceeding expectations. Valuation metrics appear attractive with a P/E of 9.29 and EV/EBITDA of 5.95, while profitability remains solid with a net income margin of 12.26% and ROE of 16.19%.
The outlook is positive given consistent earnings outperformance and a consensus price target of $29.33, implying 24% upside. Risks include high debt levels and competitive pressures in the software sector. Investor sentiment is mixed, with analysts showing cautious optimism amid recent institutional selling.
Trailing returns across standard periods
Latest headlines on both assets
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →Open Text Corporation is a global leader in Enterprise Information Management (EIM) software and solutions. The company provides a comprehensive platform that helps organizations manage, secure, and leverage their unstructured digital content, including documents, emails, and media files. OTEX's offerings span content management, business process management, customer experience management, and security, serving large enterprises across various industries worldwide.
Read more on OTEX →